“Myositis, believed to be driven by B cells, is a severe and potentially fatal autoimmune disease for which no curative therapy exists. Current treat...
NMDP BioTherapies℠, formerly Be The Match BioTherapies, announced that Tom Hochuli will serve as president, leading the organization into its promising f...
Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulti...
Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat adults with highly active relapsing remitting multi...
The round also included premier investors such as WI Harper Group, a leading cross-border venture capital firm, and SEEDS Capital, the investment arm of go...
Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of Stage 2 to follow in the second half of ...
Biocytogen’s fully human antibody sequences were generated by proprietary RenMice strains, each engineered to lack a certain drug target gene. From M...
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, de...
As part of the agreement, Armatus will leverage Andelyn’s extensive experience in adeno-associated virus (AAV) production and its proprietary suspens...
-Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that the Saudi Food and Drug Authority (SFDA) granted Marketing Authorization for CASGE...
Cell BioEngines, Inc., a clinical-stage biotechnology company focused on delivering novel, innovative stem cell and immune cell therapies to address blood ...
Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to ...
-JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida: “JCR”) announces that it has signed a Research Collaboration, Op...
Kite, a Gilead Company (Nasdaq: GILD), announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta® (axicabtage...
© 2025 Biopharma Boardroom. All Rights Reserved.
